Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
NGM Biopharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NGM
Nasdaq
8731
https://www.ngmbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for NGM Biopharmaceuticals Inc
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
- Mar 19th, 2024 9:30 pm
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
- Mar 11th, 2024 9:30 pm
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 11th, 2024 8:05 pm
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
- Mar 7th, 2024 2:15 pm
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
- Feb 26th, 2024 2:03 pm
NGM to go private through deal with investment firm
- Feb 26th, 2024 12:10 pm
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
- Feb 20th, 2024 9:01 pm
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
- Jan 17th, 2024 9:47 pm
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
- Jan 9th, 2024 1:00 pm
Great week for NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) institutional investors after losing 75% over the previous year
- Jan 3rd, 2024 2:47 pm
Here's Why We're A Bit Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Situation
- Nov 22nd, 2023 7:01 pm
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver MeetingĀ®
- Nov 13th, 2023 2:45 pm
NGM Bio to Participate in Upcoming Investor Conferences
- Nov 7th, 2023 9:05 pm
NGM Biopharmaceuticals Inc (NGM) Reports Q3 2023 Financial Results
- Nov 2nd, 2023 11:42 pm
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates
- Nov 2nd, 2023 9:25 pm
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
- Nov 2nd, 2023 8:01 pm
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver MeetingĀ®
- Oct 11th, 2023 8:05 pm
Alexandria Real Estate Equities, Inc.'s One-of-a-Kind, Essential Labspace Platform Empowers the Integration and Enhancement of Biological Discoveries Enabled by AI to Widen the Opportunities for and Accelerate the Development of Novel Medicines
- Sep 27th, 2023 12:30 pm
Strength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2% Jump Turn into More Strength?
- Sep 20th, 2023 8:26 am
Insiders Give Up US$292k As NGM Biopharmaceuticals Stock Drops To US$1.31
- Sep 17th, 2023 12:45 pm
Scroll